A new study lends depth to the understanding of endogenous Candida endophthalmitis by comparing imagery from optical coherence tomography both before and after treatment.
A new study of patients with endogenous Candida endophthalmitis (ECE) offers uses pre- and post-treatment optical coherence tomography (OCT) to generate new insights into the disease.
Endogenous endophthalmitis is caused by the spread of hematogenous spread of infectious microbes. It accounts for between 2-10% of all cases of endophthalmitis, and can lead to vision loss. Some research indicates cases of endophthalmitis are increasing among the population of East Asia. Most instances of the disease are related to Candida species, such as Candida albicans.
A team of researchers from China’s Fudan University, in Shanghai, wanted to evaluate the features of ECE using OCT images of retinal lesions. They studied 16 patients (22 eyes) who had sought treatment at the university’s hospital between January 2014 and April 2018. The team used OCT to classify the patients’ lesions into 4 discrete categories. They also found that OCT morphology of lesions correlated with visual prognosis. The findings are reported this month in BMC Ophthalmology.
“There have been very few OCT follow-up studies of ECE after treatment,” wrote corresponding author Gezhi Xu, MD, of Fudan University, noting that another recent study did not include follow-up imagery for most patients. “In our study, all 22 eyes were followed-up by OCT for at least 2 months at the same medical center, and post-treatment changes in the retinal lesions were evaluated using the eye-tracking-based follow-up function of the OCT instrument.”
Xu and colleagues found that major risk factors for ECE included intravenous use of corticosteroids or antibiotics, lithotripsy of urinary calculi, diabetes, endocarditis, gastrointestinal surgery, and abortion. Fourteen of the 22 eyes were treated with vitrectomy, and the authors confirmed previous research which found the positive rate of vitreous fungal culture was higher in vitrectomy samples than in needle biopsy samples.
While earlier work has sought to differentiate between lesion types in patients with ECE, Xu and colleagues were able to come up with 4 categories of lesions using OCT. They are as follows:
ECE causes vision loss in a high number of patients. A 2012 study found 55% of eyes with ECE suffered vision loss, and 32% of eyes suffered severe vision loss as a result of the infection. Xu and colleagues said poor baseline visual acuity and centrally located fungal lesions have been associated with poor vision outcomes in ECE.
Of the 4 categories, those with Type 2 lesions had the best prognosis, Xu and colleagues found. However, the data also showed that patients with Type 2 lesions also had the best baseline visual acuity. This might explain why all four eyes categorized as Type 2 saw improved visual acuity following antifungal therapy without vitrectomy.
In terms of complications, the team found that epiretinal membrane and subretinal fibrosis were the most common complications among patients with ECE.
Still, Xu and colleagues said the sample size was ultimately too small to draw wide conclusions about the prognoses of patients based on the 4 categories.
Reference
Zhuang, H., Ding, X., Gao, F. et al. Optical coherence tomography features of retinal lesions in Chinese patients with endogenous Candida endophthalmitis. BMC Ophthalmol 20, 52 (2020). https://doi.org/10.1186/s12886-020-01337-9.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More